HRP20230053T1 - Tableta ribocikliba - Google Patents
Tableta ribocikliba Download PDFInfo
- Publication number
- HRP20230053T1 HRP20230053T1 HRP20230053TT HRP20230053T HRP20230053T1 HR P20230053 T1 HRP20230053 T1 HR P20230053T1 HR P20230053T T HRP20230053T T HR P20230053TT HR P20230053 T HRP20230053 T HR P20230053T HR P20230053 T1 HRP20230053 T1 HR P20230053T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- coated pharmaceutical
- pharmaceutical oral
- oral tablet
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148240P | 2015-04-16 | 2015-04-16 | |
| EP16718020.7A EP3283058B1 (en) | 2015-04-16 | 2016-04-14 | Ribociclib tablet |
| PCT/IB2016/052136 WO2016166703A1 (en) | 2015-04-16 | 2016-04-14 | Ribociclib tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230053T1 true HRP20230053T1 (hr) | 2023-03-03 |
Family
ID=55806565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230053TT HRP20230053T1 (hr) | 2015-04-16 | 2016-04-14 | Tableta ribocikliba |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10799506B2 (enExample) |
| EP (3) | EP4620458A3 (enExample) |
| JP (1) | JP2018514523A (enExample) |
| KR (2) | KR102750931B1 (enExample) |
| CN (2) | CN115554257A (enExample) |
| AR (1) | AR104257A1 (enExample) |
| AU (5) | AU2016248017A1 (enExample) |
| BR (1) | BR112017021283A2 (enExample) |
| CA (1) | CA2982425C (enExample) |
| CL (1) | CL2017002593A1 (enExample) |
| CO (1) | CO2017010510A2 (enExample) |
| DK (1) | DK3283058T3 (enExample) |
| EA (1) | EA201792290A1 (enExample) |
| EC (1) | ECSP17075052A (enExample) |
| ES (1) | ES2938261T3 (enExample) |
| FI (1) | FI3283058T3 (enExample) |
| HR (1) | HRP20230053T1 (enExample) |
| HU (1) | HUE061213T2 (enExample) |
| IL (1) | IL254818A0 (enExample) |
| MX (1) | MX2017013350A (enExample) |
| PE (1) | PE20180035A1 (enExample) |
| PH (1) | PH12017501820A1 (enExample) |
| PL (1) | PL3283058T3 (enExample) |
| PT (1) | PT3283058T (enExample) |
| SG (1) | SG11201708084PA (enExample) |
| SI (1) | SI3283058T1 (enExample) |
| TN (1) | TN2017000422A1 (enExample) |
| TW (1) | TW201642864A (enExample) |
| WO (1) | WO2016166703A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018514523A (ja) * | 2015-04-16 | 2018-06-07 | ノバルティス アーゲー | リボシクリブ錠剤 |
| CA3048036A1 (en) | 2018-07-02 | 2020-01-02 | Apotex Inc | Novel crystalline form of ribociclib succinate |
| EP4021450B1 (en) | 2019-08-26 | 2025-11-05 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| IL293940A (en) | 2019-12-16 | 2022-08-01 | Lunella Biotech Inc | Selective cancer drugs cdk4/6 inhibitors |
| CA3164619A1 (en) | 2019-12-16 | 2021-06-24 | Lunella Biotech, Inc. | Selective cdk4/6 inhibitor cancer therapeutics |
| US20230310327A1 (en) * | 2020-08-03 | 2023-10-05 | Natco Pharma Limited | Pharmaceutical compositions comprising ribociclib |
| KR20230079187A (ko) * | 2020-09-29 | 2023-06-05 | 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. | 고지혈증 및 심혈관 질환의 치료 및 예방을 위한 스타틴 및 피브레이트의 약학적 병용 |
| WO2022162122A1 (en) | 2021-01-29 | 2022-08-04 | Biotx.Ai Gmbh | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection |
| TWI848533B (zh) | 2022-01-25 | 2024-07-11 | 瑞士商諾華公司 | 瑞博西尼藥物組成物 |
| TWI866427B (zh) | 2022-08-31 | 2024-12-11 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| AU2024244511A1 (en) | 2023-03-27 | 2025-09-25 | Novartis Ag | Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor |
| WO2025219830A1 (en) | 2024-04-15 | 2025-10-23 | Novartis Ag | Pharmaceutical compositions of ribociclib |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5428812A (en) * | 1977-08-09 | 1979-03-03 | Yoshitomi Pharmaceut Ind Ltd | Preparation of coated tablet |
| GB9414045D0 (en) | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| EP0771339B1 (en) * | 1994-07-12 | 2003-10-15 | BPSI Holdings, Inc. | Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith |
| US6448323B1 (en) * | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| US8343533B2 (en) * | 2009-09-24 | 2013-01-01 | Mcneil-Ppc, Inc. | Manufacture of lozenge product with radiofrequency |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| EA025033B1 (ru) * | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| IN2015DN01046A (enExample) * | 2012-07-13 | 2015-06-26 | Gtx Inc | |
| EP3251673A1 (en) * | 2012-12-13 | 2017-12-06 | IP Gesellschaft für Management mbH | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
| WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
| PT2976106T (pt) * | 2013-03-21 | 2021-05-26 | Array Biopharma Inc | Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor |
| EP2810644A1 (en) * | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| JP2018514523A (ja) * | 2015-04-16 | 2018-06-07 | ノバルティス アーゲー | リボシクリブ錠剤 |
| CN109953966A (zh) * | 2017-12-26 | 2019-07-02 | 天津耀辰实业发展有限公司 | 一种含有瑞博西尼的药物组合物及其制备方法 |
| JP7347388B2 (ja) | 2020-09-25 | 2023-09-20 | 信越化学工業株式会社 | 紫外線硬化型有機変性シリコーン組成物および硬化物 |
-
2016
- 2016-04-14 JP JP2017553915A patent/JP2018514523A/ja active Pending
- 2016-04-14 PL PL16718020.7T patent/PL3283058T3/pl unknown
- 2016-04-14 ES ES16718020T patent/ES2938261T3/es active Active
- 2016-04-14 PE PE2017002096A patent/PE20180035A1/es unknown
- 2016-04-14 TN TNP/2017/000422A patent/TN2017000422A1/en unknown
- 2016-04-14 HR HRP20230053TT patent/HRP20230053T1/hr unknown
- 2016-04-14 DK DK16718020.7T patent/DK3283058T3/da active
- 2016-04-14 BR BR112017021283A patent/BR112017021283A2/pt not_active Application Discontinuation
- 2016-04-14 PT PT167180207T patent/PT3283058T/pt unknown
- 2016-04-14 SG SG11201708084PA patent/SG11201708084PA/en unknown
- 2016-04-14 EA EA201792290A patent/EA201792290A1/ru unknown
- 2016-04-14 FI FIEP16718020.7T patent/FI3283058T3/fi active
- 2016-04-14 MX MX2017013350A patent/MX2017013350A/es unknown
- 2016-04-14 KR KR1020177029433A patent/KR102750931B1/ko active Active
- 2016-04-14 EP EP25194967.3A patent/EP4620458A3/en active Pending
- 2016-04-14 CN CN202211237232.XA patent/CN115554257A/zh active Pending
- 2016-04-14 CA CA2982425A patent/CA2982425C/en active Active
- 2016-04-14 SI SI201631661T patent/SI3283058T1/sl unknown
- 2016-04-14 KR KR1020257000051A patent/KR20250009572A/ko active Pending
- 2016-04-14 US US15/564,534 patent/US10799506B2/en active Active
- 2016-04-14 CN CN201680022122.8A patent/CN107530292B/zh active Active
- 2016-04-14 EP EP16718020.7A patent/EP3283058B1/en active Active
- 2016-04-14 AU AU2016248017A patent/AU2016248017A1/en not_active Abandoned
- 2016-04-14 AR ARP160101012A patent/AR104257A1/es unknown
- 2016-04-14 HU HUE16718020A patent/HUE061213T2/hu unknown
- 2016-04-14 WO PCT/IB2016/052136 patent/WO2016166703A1/en not_active Ceased
- 2016-04-14 EP EP22203730.1A patent/EP4197530B1/en active Active
- 2016-04-15 TW TW105111921A patent/TW201642864A/zh unknown
-
2017
- 2017-10-01 IL IL254818A patent/IL254818A0/en unknown
- 2017-10-04 PH PH12017501820A patent/PH12017501820A1/en unknown
- 2017-10-13 CO CONC2017/0010510A patent/CO2017010510A2/es unknown
- 2017-10-13 CL CL2017002593A patent/CL2017002593A1/es unknown
- 2017-11-10 EC ECIEPI201775052A patent/ECSP17075052A/es unknown
-
2019
- 2019-03-20 AU AU2019201929A patent/AU2019201929B2/en active Active
-
2020
- 2020-08-26 US US17/003,771 patent/US20200390771A1/en not_active Abandoned
- 2020-10-06 AU AU2020250190A patent/AU2020250190A1/en not_active Abandoned
-
2022
- 2022-06-08 US US17/805,956 patent/US12064434B2/en active Active
- 2022-08-08 AU AU2022215155A patent/AU2022215155B2/en active Active
-
2024
- 2024-02-27 US US18/588,259 patent/US20250090531A1/en active Pending
- 2024-10-31 AU AU2024227794A patent/AU2024227794A1/en active Pending
- 2024-12-11 US US18/977,228 patent/US12419894B2/en active Active
- 2024-12-11 US US18/977,210 patent/US20250134893A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230053T1 (hr) | Tableta ribocikliba | |
| JP2018514523A5 (enExample) | ||
| MX375936B (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
| BR112017002777A2 (pt) | formulação compreendendo partículas | |
| HUE061174T2 (hu) | 1,3,4-oxadiazol-szulfonamid-származék vegyületek mint hiszton-deacetiláz-6 inhibitorok, és az ilyen vegyületeket tartalmazó gyógyszerkészímény | |
| MX2020000332A (es) | Preparacion que comprende vonoprazan. | |
| TN2014000442A1 (en) | A delayed release drug formulation | |
| WO2016054528A8 (en) | Degradable materials and packaging made from same | |
| HRP20192119T1 (hr) | Pripravak i metoda za pomoć pri spavanju | |
| BR112012004967B8 (pt) | forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis, seu uso e seu método de produção | |
| JP2014218522A5 (enExample) | ||
| UA117260C2 (uk) | Лікарський препарат з відстроченим вивільненням | |
| MX380566B (es) | Composición oral que comprende una primera población de microesferas con un ingrediente activo susceptible o con potencial de abuso y una segunda población de microesferas con óxido de polietileno y un recubrimiento permeable o semipermeable. | |
| HRP20210183T1 (hr) | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate | |
| MX2019012757A (es) | Composicion farmaceutica para administracion oral que comprende enzalutamida. | |
| WO2016140933A3 (en) | Immediate release soluble ibuprofen compositions | |
| WO2015092811A3 (en) | Oral films | |
| BR112015001919A2 (pt) | método de proteger uma substância ativa a partir da degradação durante peletização de uma ração ou concentrado contendo a substância ativa | |
| EP3400964A4 (en) | TASTE-MASKED AND ORAL ADMINISTRATIVE PHARMACEUTICAL PREPARATION WITH VARENICLIN OR PHARMACEUTICAL SALT OF IT | |
| PH12017500269A1 (en) | Composite formulation for oral administration comprising omega-3 fatty acid esters and statins | |
| FI3509595T3 (fi) | Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita | |
| CN106687453A8 (zh) | 作为溴结构域抑制剂的四氢喹啉衍生物 | |
| JP2016513680A5 (enExample) | ||
| HK1220113A1 (zh) | 药物软明胶胶囊剂型 | |
| EP3216450A8 (en) | Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereof |